Jennison Associates LLC purchased a new stake in Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 386,426 shares of the company’s stock, valued at approximately $8,687,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ANRO. Revisor Wealth Management LLC acquired a new stake in Alto Neuroscience during the 1st quarter worth approximately $385,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Alto Neuroscience in the first quarter valued at approximately $538,000. XTX Topco Ltd raised its stake in shares of Alto Neuroscience by 32.2% during the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after purchasing an additional 5,078 shares during the last quarter. Ikarian Capital LLC raised its stake in shares of Alto Neuroscience by 368.2% during the fourth quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock worth $9,167,000 after purchasing an additional 405,000 shares during the last quarter. Finally, Vestal Point Capital LP lifted its holdings in shares of Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after purchasing an additional 1,535,000 shares during the period.
Analysts Set New Price Targets
ANRO has been the topic of a number of analyst reports. Chardan Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Wedbush raised their target price on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Robert W. Baird lowered their target price on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. JonesTrading dropped their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Finally, Bank of America initiated coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They set a “buy” rating and a $35.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $35.25.
Alto Neuroscience Price Performance
Shares of NYSE:ANRO opened at $26.89 on Wednesday. The firm has a market capitalization of $943.57 million, a price-to-earnings ratio of -11.11 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The business’s 50 day simple moving average is $23.25 and its 200-day simple moving average is $21.32. Alto Neuroscience, Inc. has a 12 month low of $2.72 and a 12 month high of $28.85.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, equities analysts forecast that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.
About Alto Neuroscience
Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.
Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.
Featured Articles
- Five stocks we like better than Alto Neuroscience
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Want to see what other hedge funds are holding ANRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alto Neuroscience, Inc. (NYSE:ANRO – Free Report).
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
